409 related articles for article (PubMed ID: 18651980)
1. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.
Moser C; Lang SA; Mori A; Hellerbrand C; Schlitt HJ; Geissler EK; Fogler WE; Stoeltzing O
BMC Cancer; 2008 Jul; 8():206. PubMed ID: 18651980
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
3. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling.
Liu P; Atkinson SJ; Akbareian SE; Zhou Z; Munsterberg A; Robinson SD; Bao Y
Sci Rep; 2017 Oct; 7(1):12651. PubMed ID: 28978924
[TBL] [Abstract][Full Text] [Related]
5. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
[TBL] [Abstract][Full Text] [Related]
7. Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells.
Jung JE; Kim HS; Lee CS; Park DH; Kim YN; Lee MJ; Lee JW; Park JW; Kim MS; Ye SK; Chung MH
Carcinogenesis; 2007 Aug; 28(8):1780-7. PubMed ID: 17557905
[TBL] [Abstract][Full Text] [Related]
8. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Puppo M; Battaglia F; Ottaviano C; Delfino S; Ribatti D; Varesio L; Bosco MC
Mol Cancer Ther; 2008 Jul; 7(7):1974-84. PubMed ID: 18645007
[TBL] [Abstract][Full Text] [Related]
9. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.
LaVallee TM; Burke PA; Swartz GM; Hamel E; Agoston GE; Shah J; Suwandi L; Hanson AD; Fogler WE; Sidor CF; Treston AM
Mol Cancer Ther; 2008 Jun; 7(6):1472-82. PubMed ID: 18566218
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells.
Carbajo-Pescador S; Ordoñez R; Benet M; Jover R; García-Palomo A; Mauriz JL; González-Gallego J
Br J Cancer; 2013 Jul; 109(1):83-91. PubMed ID: 23756865
[TBL] [Abstract][Full Text] [Related]
11. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
12. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
[TBL] [Abstract][Full Text] [Related]
13. GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway.
Lu S; Gao Y; Huang X; Wang X
Int J Oncol; 2014 Apr; 44(4):1259-67. PubMed ID: 24535538
[TBL] [Abstract][Full Text] [Related]
14. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
15. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
Wu J; Xu X; Wu S; Shi W; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
Cancer Med; 2023 Sep; 12(17):18078-18097. PubMed ID: 37563971
[TBL] [Abstract][Full Text] [Related]
16. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
Lang SA; Moser C; Gaumann A; Klein D; Glockzin G; Popp FC; Dahlke MH; Piso P; Schlitt HJ; Geissler EK; Stoeltzing O
Clin Cancer Res; 2007 Nov; 13(21):6459-68. PubMed ID: 17975158
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma.
Chai ZT; Kong J; Zhu XD; Zhang YY; Lu L; Zhou JM; Wang LR; Zhang KZ; Zhang QB; Ao JY; Wang M; Wu WZ; Wang L; Tang ZY; Sun HC
PLoS One; 2013; 8(10):e77957. PubMed ID: 24194905
[TBL] [Abstract][Full Text] [Related]
18. Anticancer and Antiangiogenic Activities of Novel α-Mangostin Glycosides in Human Hepatocellular Carcinoma Cells via Downregulation of c-Met and HIF-1α.
Kim SM; Han JM; Le TT; Sohng JK; Jung HJ
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32516967
[TBL] [Abstract][Full Text] [Related]
19. The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis.
Oh SY; Seok JY; Choi YS; Lee SH; Bae JS; Lee YM
Mol Cells; 2015 Jun; 38(6):528-34. PubMed ID: 26013382
[TBL] [Abstract][Full Text] [Related]
20. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Yeo EJ; Chun YS; Cho YS; Kim J; Lee JC; Kim MS; Park JW
J Natl Cancer Inst; 2003 Apr; 95(7):516-25. PubMed ID: 12671019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
